ZA200608998B - Imidazole derivatives as tyrosine kinase inhibitors - Google Patents

Imidazole derivatives as tyrosine kinase inhibitors

Info

Publication number
ZA200608998B
ZA200608998B ZA200608998A ZA200608998A ZA200608998B ZA 200608998 B ZA200608998 B ZA 200608998B ZA 200608998 A ZA200608998 A ZA 200608998A ZA 200608998 A ZA200608998 A ZA 200608998A ZA 200608998 B ZA200608998 B ZA 200608998B
Authority
ZA
South Africa
Prior art keywords
tyrosine kinase
kinase inhibitors
imidazole derivatives
imidazole
derivatives
Prior art date
Application number
ZA200608998A
Other languages
English (en)
Inventor
Holzemann Guenter
Jonczyk Alfred
Sutter Arne
Mitjans Francesc
Adan Jaume
Crassier Helene
Stahle Wolfgang
Rautenberg Wilfried
Rosell-Vives Elisabet
Soler Riera Marta
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA200608998B publication Critical patent/ZA200608998B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88Nitrogen atoms, e.g. allantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200608998A 2004-03-29 2006-10-30 Imidazole derivatives as tyrosine kinase inhibitors ZA200608998B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004015099A DE102004015099A1 (de) 2004-03-29 2004-03-29 Imidazolderivate

Publications (1)

Publication Number Publication Date
ZA200608998B true ZA200608998B (en) 2008-07-30

Family

ID=34981611

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200608998A ZA200608998B (en) 2004-03-29 2006-10-30 Imidazole derivatives as tyrosine kinase inhibitors

Country Status (13)

Country Link
US (1) US20070225347A1 (es)
EP (1) EP1761503A2 (es)
JP (1) JP2007530609A (es)
KR (1) KR20060132965A (es)
CN (1) CN1938282A (es)
AR (1) AR048327A1 (es)
AU (1) AU2005231907A1 (es)
BR (1) BRPI0508881A (es)
CA (1) CA2561585A1 (es)
DE (1) DE102004015099A1 (es)
RU (1) RU2006138150A (es)
WO (1) WO2005097755A2 (es)
ZA (1) ZA200608998B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076592A1 (en) * 2005-01-14 2006-07-20 Cgi Pharmaceuticals, Inc. 1,3 substituted diaryl ureas as modulators of kinase activity
WO2007024294A2 (en) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
EP2004631A1 (en) * 2006-04-12 2008-12-24 Merck Patent GmbH N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
CN103910714A (zh) * 2013-01-09 2014-07-09 天津泰瑞倍药研科技有限公司 氟代环丁烷基咪唑类化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
AU2002366440A1 (en) * 2001-09-27 2003-09-09 Smithkline Beecham Corporation Chemical compounds

Also Published As

Publication number Publication date
DE102004015099A1 (de) 2005-10-20
WO2005097755A3 (de) 2006-03-09
EP1761503A2 (de) 2007-03-14
AR048327A1 (es) 2006-04-19
WO2005097755A2 (de) 2005-10-20
RU2006138150A (ru) 2008-05-10
BRPI0508881A (pt) 2007-09-11
CA2561585A1 (en) 2005-10-20
JP2007530609A (ja) 2007-11-01
US20070225347A1 (en) 2007-09-27
AU2005231907A1 (en) 2005-10-20
CN1938282A (zh) 2007-03-28
KR20060132965A (ko) 2006-12-22

Similar Documents

Publication Publication Date Title
IL186845A0 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
IL177007A0 (en) 2-(3-substituted-aryl) amino-4-thiazoles as tyrosine kinase inhibitors
IL174258A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
IL174261A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
ZA200606683B (en) Pyrazolotriazines as kinase inhibitors
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
AP2007003924A0 (en) Imidazopyrazine as tyrosine kinase inhibitors
HK1135391A1 (en) Triazole derivatives as kinase inhibitors
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
HK1117523A1 (en) Substituted benzimidazoles as kinase inhibitors
HK1104286A1 (en) Pyrimidine urea derivatives as kinase inhibitors
HK1163677A1 (zh) 可用作激酶抑制劑的吡唑基氨基吡啶衍生物
EP2040546A4 (en) TYROSINE KINASE INHIBITORS
ZA200900019B (en) Tyrosine kinase inhibitors
PL1896422T3 (pl) Inhibitory kinazy tyrozynowej
ZA200608998B (en) Imidazole derivatives as tyrosine kinase inhibitors
IL184798A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
ZA200703835B (en) Heterocyclic substituted bisarylurea derivatives as kinase inhibitors
EP1951252A4 (en) INHIBITORS OF TYROSINE KINASES
ZA200800506B (en) Substituted benzimidazoles as kinase inhibitors
ZA200709732B (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
SI1684750T1 (sl) aminoariloksazolne spojine kot inhibitorji tirozin kinaze
ZA200609510B (en) Pyrimidine urea derivatives as kinase inhibitors